Retatrutide and trizepatide represent a novel class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These combined receptor agonists https://shaunarkew189472.isblog.net/new-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide-55772356